Overview
ProteoNic BioSciences offers proprietary vector technologies like 2G UNic™ to pharmaceutical, biotech, and CDMO companies for enhancing protein production, viral vector titers, and gene expression in mammalian, yeast, and fungal cells. The technology optimizes mRNA translation, boosts yields for complex proteins such as multi-specific antibodies, and lowers production costs through non-exclusive worldwide licensing. Validated across common expression platforms, it supports biologics and gene therapy manufacturing with customization options.
Frequently asked questions
- What capabilities does ProteoNic offer for protein production?
- ProteoNic provides 2G UNic™ vector technology to boost transcription, translation, and yields for complex proteins in mammalian, yeast, and fungal cells, including viral vectors and multi-specific antibodies.
- What are the licensing terms and geographies?
- Licenses are non-exclusive and worldwide to pharmaceutical, biotech, and CDMO clients, with options for vectors, transfection-ready DNA, protocols, and custom variants.
- Is ProteoNic's technology validated and regulatory-ready?
- 2G UNic™ vectors are extensively validated in commercial mammalian platforms like CHO cells and available with expert support and protocols for manufacturing.